{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:49:11Z","timestamp":1790689751794,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":586,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1038\/mt.2014.224","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T07:15:30Z","timestamp":1416467730000},"page":"456-464","source":"Crossref","is-referenced-by-count":37,"title":["Enzyme Enhancers for the Treatment of Fabry and Pompe Disease"],"prefix":"10.1016","volume":"23","author":[{"given":"Jan","family":"Lukas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Pockrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Seemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Runge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Pohlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaonan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gl\u00e4ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Beller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Rolfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Katrin","family":"Giese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2014.224_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2004.03.062","article-title":"Crystal structure of alpha-galactosidase from Trichoderma reesei and its complex with galactose: implications for catalytic mechanism","volume":"339","author":"Golubev","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1038\/mt.2014.224_bib2","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2014.224_bib3","first-page":"769","article-title":"Mass spectrometry in the study of lysosomal storage disorders","volume":"49","author":"Meikle","year":"2003","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"10.1038\/mt.2014.224_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"key":"10.1038\/mt.2014.224_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.c.31324","article-title":"The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management","volume":"160C","author":"Kishnani","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1038\/mt.2014.224_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"G\u00fcng\u00f6r","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1038\/mt.2014.224_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2014.224_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1038\/mt.2014.224_bib9","doi-asserted-by":"crossref","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1038\/mt.2014.224_bib10","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.biocel.2005.05.008","article-title":"Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease","volume":"37","author":"Schmitz","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1038\/mt.2014.224_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J"},{"key":"10.1038\/mt.2014.224_bib12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2014.224_bib13","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ymgme.2011.12.012","article-title":"Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction","volume":"105","author":"Coutinho","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2014.224_bib14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMra0907180","article-title":"New therapeutic approaches to mendelian disorders","volume":"363","author":"Dietz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2014.224_bib15","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1542\/peds.2007-0388","article-title":"Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations","volume":"120","author":"Kemper","year":"2007","journal-title":"Pediatrics"},{"key":"10.1038\/mt.2014.224_bib16","first-page":"CD006663","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"5","author":"El Dib","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1038\/mt.2014.224_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2014.224_bib18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2014.224_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2014.224_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"10.1038\/mt.2014.224_bib21","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1038\/mt.2014.224_bib22","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2014.224_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","article-title":"Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II","volume":"90","author":"Okumiya","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2014.224_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.224_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1750-1172-6-66","article-title":"Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests","volume":"6","author":"Andreotti","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1038\/mt.2014.224_bib26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2014.224_bib27","article-title":"Method to predict response to pharmacological chaperone treatment of diseases","author":"Benjamin","year":"2014","journal-title":"Amicus Therapeutics: USA"},{"key":"10.1038\/mt.2014.224_bib28","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2014.224_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1038\/mt.2014.224_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bcmd.2008.11.002","article-title":"Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease","volume":"42","author":"S\u00e1nchez-Oll\u00e9","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"10.1038\/mt.2014.224_bib31","doi-asserted-by":"crossref","first-page":"17400","DOI":"10.1073\/pnas.1203924109","article-title":"Pharmacological chaperones for human \u03b1-N-acetylgalactosaminidase","volume":"109","author":"Clark","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2014.224_bib32","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases","volume":"134","author":"Mu","year":"2008","journal-title":"Cell"},{"key":"10.1038\/mt.2014.224_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1021\/cb100321m","article-title":"Ca2+ homeostasis modulation enhances the amenability of L444P glucosylcerebrosidase to proteostasis regulation in patient-derived fibroblasts","volume":"6","author":"Wang","year":"2011","journal-title":"ACS Chem Biol"},{"key":"10.1038\/mt.2014.224_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/8904_2011_49","article-title":"Treatment of Human Fibroblasts Carrying NPC1 Missense Mutations with MG132 Leads to an Improvement of Intracellular Cholesterol Trafficking","volume":"2","author":"Zampieri","year":"2012","journal-title":"JIMD Rep"},{"key":"10.1038\/mt.2014.224_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1172-5-36","article-title":"Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study","volume":"5","author":"Andreotti","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1038\/mt.2014.224_bib36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2337\/diabetes.55.03.06.db05-0832","article-title":"The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment","volume":"55","author":"Marfella","year":"2006","journal-title":"Diabetes"},{"key":"10.1038\/mt.2014.224_bib37","doi-asserted-by":"crossref","first-page":"13192","DOI":"10.1073\/pnas.0705637104","article-title":"Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease","volume":"104","author":"Zheng","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2014.224_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.chembiol.2006.12.006","article-title":"High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones","volume":"14","author":"Tropak","year":"2007","journal-title":"Chem Biol"},{"key":"10.1038\/mt.2014.224_bib39","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1038\/mt.2014.224_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-6-19","article-title":"TRPM8 and Nav1.8 sodium channels are required for transthyretin-induced calcium influx in growth cones of small-diameter TrkA-positive sensory neurons","volume":"6","author":"Gasperini","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.1038\/mt.2014.224_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1755-5949.2007.00032.x","article-title":"Ambroxol: a CNS drug?","volume":"14","author":"Weiser","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1038\/mt.2014.224_bib42","doi-asserted-by":"crossref","first-page":"28386","DOI":"10.1074\/jbc.M112.351056","article-title":"\u03b1-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants","volume":"287","author":"Siekierska","year":"2012","journal-title":"J Biol Chem"},{"issue":"Pt 5","key":"10.1038\/mt.2014.224_bib43","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1038\/mt.2014.224_bib44","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological enhancement of \u03b1-glucosidase by the allosteric chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.224_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem J"},{"key":"10.1038\/mt.2014.224_bib46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/oby.2008.616","article-title":"PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal","volume":"17","author":"Kilroy","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1038\/mt.2014.224_bib47","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/ncomms2270","article-title":"PPAR\u03b3 is an E3 ligase that induces the degradation of NF\u03baB\/p65","volume":"3","author":"Hou","year":"2012","journal-title":"Nat Commun"},{"key":"10.1038\/mt.2014.224_bib48","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/hmg\/ddq292","article-title":"Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease","volume":"19","author":"Ron","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2014.224_bib49","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/hmg\/dds535","article-title":"ITCH regulates degradation of mutant glucocerebrosidase: implications to Gaucher disease","volume":"22","author":"Maor","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2014.224_bib50","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2014.224_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.224_bib52","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid \u03b1-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/mt.2014.224_bib53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J Inherit Metab Dis"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616300594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616300594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T12:21:32Z","timestamp":1538050892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616300594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1525001616300594"],"URL":"https:\/\/doi.org\/10.1038\/mt.2014.224","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}